The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
Open accessAbstract
Interleukin 1β (IL-1β) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1β. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1β production in vitro. Processing of IL-1β initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1β in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that induce interleukin (IL)-1β release to recruit macrophages and enhance local islet inflammation ( 45 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“A potential role for NLRP3 in promoting elevated levels of IL-1β in type 2 diabetes was also implied by the observation of NLRP3-dependent IL-1β secretion by mouse bone marrow-derived macrophages and dendritic cells in response to islet amyloid polypeptide (IAPP), which is deposited in the pancreas and associated with loss of β-cell function in type 2 diabetes61.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [61]
In the citing paper
“Interestingly, the anti-diabetic drug glyburide (Glibenclamide; Roche/Sanofi-Aventis) has been shown to block glucose-mediated secretion of IL-1β by mouse pancreatic islets62, as well as IL-1β production by macrophages in response to IAPP61, and NLRP3-deficient mice were more glucose tolerant than wild-type mice62.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [61]
In the citing paper
“In a separate study, no differences in IL-1β secretion were observed between wild-type and TXNIP-deficient bone marrow-derived macrophages in response to several NLRP3 stimuli, including MSU crystals and ATP61.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [61]
In the citing paper
“However, the role of TXNIP and ROS in NLRP3 activation has been challenged.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Self-citationGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Self-citationTLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
Bauernfeind, F. G., Horvath, G. L., Stutz, A., Alnemri, E. S., MacDonald, K. L., Speert, D. P., Fernandes‐Alnemri, T., Wu, J., Monks, B. G., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901363 · Cited by 3,087
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Inoue, H., Shirakawa, J., Togashi, Y., Tajima, K., Okuyama, T., Kyohara, M., Tanaka, Y., Orime, K., Saisho, Y., Yamada, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809228 · Cited by 43
“Chronic hyperglycemia promotes amyloid formation in the islets by inducing the secretion of islet amyloid polypeptide (IAPP) (12), production of reactive oxygen species (ROS) in βcells (13), and formation of advanced glycation end products (AGE) (14,15).”
BackgroundPriming of NLRP3 inflammasome activation by Msn kinase MINK1 in macrophages
Zhu, K., Jin, X., Chi, Z., Chen, S., Wu, S., Sloan, R. D., Lin, X., Neculai, D., Wang, D., Hu, H., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00761-1 · Cited by 46
Is immunity a mechanism contributing to statin-induced diabetes?
Henriksbo, B. D., & Schertzer, J. D. (2015) · Adipocyte · doi:10.1080/21623945.2015.1024394 · Cited by 46
“Further, it will be important to position insulin resistance in context with statininduced changes in insulin secretion, given that NLRP3 inflammasome in the pancreas and resident immune cells have been implicated in type 2 diabetes.(45,80,81) Many mechanistic questions remain about the connection between statins, NLR…”
BackgroundZhong, Y., Zhang, X., Feng, R., Fan, Y., Zhang, Z., Zhang, Q., Wan, J., Wang, Y., Yu, H., & Li, G. (2024) · Medicinal Research Reviews · doi:10.1002/med.22068 · Cited by 43
“77 mtDNA is oxidized by ROS to form ox ‐ mtDNA, co ‐ activating NLRP3 and triggering caspase ‐ 1 maturation, leading to the activation of IL ‐ 1 β and IL ‐ 18.”
How biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes
Böni‐Schnetzler, M., & Donath, M. Y. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04297.x · Cited by 45
El-Horany, H., Abd-Ellatif, R., Watany, M., Hafez, Y., & Okda, H. (2017) · IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology · doi:10.1002/iub.1645 · Cited by 41
Mapping Txnip: Key connexions in progression of diabetic nephropathy
Kumar, A., & Mittal, R. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.12.008 · Cited by 42
NALP3 inflammasome activation in protein misfolding diseases
Shi, F., Kouadir, M., & Yang, Y. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.011 · Cited by 42
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 45
The role of the inflammasome in cardiovascular diseases
Li, X., Deroide, N., & Mallat, Z. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1144-3 · Cited by 43
“diabetes [1, 2], neurodegenerative disease [3], gout [4], Crohn’s disease [5], cancer [6], irritable bowel disease [7],”
BackgroundSamaan, M. C., Marcinko, K., Sikkema, S. R., Fullerton, M. D., Ziafazeli, T., Khan, M. I., & Steinberg, G. R. (2014) · Physiological Reports · doi:10.14814/phy2.12012 · Cited by 44
“We found that exercise training tended to reduce IL-1b mRNA expression, but the effects on protein expression were much more dramatic, with IL-1b expression being reduced by approximately 70% compared to HFD Sed controls.”
BackgroundInfluentialPark, Y. J., Warnock, G. L., Ao, Z., Safikhan, N., Meloche, M. R., Asadi, A., Kieffer, T. J., & Marzban, L. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12873 · Cited by 41
“Lyophilized hIAPP (1-37) or rIAPP peptides (Bachem, Torrance, California) were prepared as previously(6) and freshly dissolved in culture medium before adding to cells at a final concentration of 10 μmol/L.”
MethodThe inhibitor effect of RKIP on inflammasome activation and inflammasome-dependent diseases
Qin, Q., Liu, H., Shou, J., Jiang, Y., Yu, H. B., & Wang, X. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00525-3 · Cited by 42
Self-assembled peptide nanorod vaccine confers protection against influenza A virus
Zottig, X., Soultan, A. H., Côté‐Cyr, M., Calzas, C., Goffic, R. L., Chevalier, C., Archambault, D., & Bourgault, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120672 · Cited by 43
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances
Mukherjee, N., Lin, L., Contreras, C., & Templin, A. T. (2021) · Metabolites · doi:10.3390/metabo11110796 · Cited by 44
Inflammation as a Sensor of Metabolic Stress in Obesity and Type 2 Diabetes
Donath, M. Y. (2011) · Endocrinology · doi:10.1210/en.2011-1691 · Cited by 43
Rangel-Salazar, R., Lindholm, M., Aguilar-Salinas, C. A., Alvarado‐Caudillo, Y., Døssing, K. B. V., Esteller, M., Labourier, E., Lund, G., Nielsen, F. C., Rodríguez‐Ríos, D., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-582 · Cited by 40
“Furthermore, native LDL is a poor activator of the NLRP3 inflammasome, a protein complex involved in IL-1beta production, compared with corresponding oxidised versions [39].”
BackgroundNuclear factor of activated T-cells (NFAT) regulation of IL-1β-induced retinal vascular inflammation
Giblin, M. J., Smith, T. E., Winkler, G. A., Pendergrass, H. A., Kim, M. J., Capozzi, M. E., Yang, R., McCollum, G. W., & Penn, J. S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166238 · Cited by 41
Pediatric obesity and severe asthma: Targeting pathways driving inflammation
Cicco, M. D., Ghezzi, M., Kantar, A., Song, W., Bush, A., Peroni, D. G., & D’Auria, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106658 · Cited by 47
“In obese AT, NLRP3 inflammasome is also activated due to exposure to saturated fatty acids, such as palmitate and stearate, and oxidative stress [89].”
Li, Z., Chen, Y., Jiang, X., Lu, P., Wang, C., Li, Z., Yu, X., Yang, Z., Ma, S., Du, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00894 · Cited by 42
Schroeder, H. T., Muller, C. H. D. L., Heck, T. G., Krause, M. D. S., & de Bittencourt, P. I. H. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.01.002 · Cited by 44
Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond
Agyemang, A. F., Harrison, S. R., Siegel, R. M., & McDermott, M. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0496-2 · Cited by 41
Miodek, A., Vidić, J., Sauriat-Dorizon, H., Richard, C.-A., Goffic, R. L., Korri‐Youssoufi, H., & Chevalier, C. (2014) · Analytical Chemistry · doi:10.1021/ac5018056 · Cited by 45
Evidence against a role for NLRP3-driven islet inflammation in db/db mice
Kammoun, H. L., Allen, T. L., Henstridge, D. C., Barre, S., Coll, R. C., Lancaster, G. I., Cron, L., Reibe, S., Chan, J. Y., Bensellam, M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.001 · Cited by 45
“Given the current literature and work from our own group [12], we were surprised to observe no increase in the mRNA expression of either IL-1b or NLRP3 in the cDNA extracted from db/db islets compared with that obtained the db/þ islets (Figure 4A,B).”
BackgroundResultSelf-citationXin, Y., Wang, X., Luo, L., & Meng, F. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b11078 · Cited by 40
Adipokines in healthy skeletal muscle and metabolic disease
Coles, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27511-6_6 · Cited by 39
NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies
Chen, P., & Li, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1430236 · Cited by 47
Novotny, G. W., Lundh, M., Backe, M. B., Christensen, D. P., Hansen, J. B., Dahllöf, M. S., Pallesen, E. M. H., & Mandrup-Poulsen, T. R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.09.014 · Cited by 37
You, L., Fang, Z., Shen, G.-M., Wang, Q., He, Y., Ye, S., Wang, L., Hu, M., Lin, Y., Liu, M., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9812 · Cited by 41
NLRP3 inflammasome inhibitor cucurbitacin B suppresses gout arthritis in mice
Xue, Y., Li, R., Fang, P., Ye, Z.-Q., Zhao, Y. L., Zhou, Y., Zhang, K., & Li, L. (2021) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0305 · Cited by 41
Metabolic Syndrome: Is Nlrp3 Inflammasome a Trigger or a Target of Insulin Resistance?
Mori, M. A., Bézy, O., & Kahn, C. R. (2011) · Circulation Research · doi:10.1161/res.0b013e318220b57b · Cited by 39
Kim, M., Yang, J., Ahn, W.-Y., & Choi, H. J. (2021) · Journal of Medical Internet Research · doi:10.2196/27218 · Cited by 41
Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes
Burg, A. R., & Tse, H. M. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7243 · Cited by 40
Pancreatic islet dysfunction in type 2 diabetes mellitus
Hu, F., Qiu, X., & Bu, S. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1510967 · Cited by 36
Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors
Harrison, D., Boutard, N., Brzózka, K. D., Bugaj, M., Chmielewski, S., Cierpich, A., Doedens, J. R., Fabritius, C., Gabel, C. A., Gałȩzowski, M., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127560 · Cited by 38
Matsuoka, T., Yoshimatsu, G., Sakata, N., Kawakami, R., Tanaka, T., Yamada, T., Yoshida, Y., Hasegawa, S., & Kodama, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74786-3 · Cited by 38
Interleukin-38 in Health and Disease
de Graaf, D. M., Teufel, L. U., Joosten, L. A. B., & Dinarello, C. A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155824 · Cited by 40
The role of caspase-8 in amyloid-induced beta cell death in human and mouse islets
Park, Y. J., Woo, M., Kieffer, T. J., Hakem, R., Safikhan, N., Yang, F., Ao, Z., Warnock, G. L., & Marzban, L. (2014) · Diabetologia · doi:10.1007/s00125-013-3152-1 · Cited by 38
“Both macrophage-positive and macrophage-negative islet areas have been reported in hIAPP transgenic mouse islets [46].”
BackgroundAston‐Mourney, K., Subramanian, S. L., Zraika, S., Samarasekera, T., Meier, D. T., Goldstein, L. C., & Hull, R. L. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00025.2013 · Cited by 37
“In fact, we and others (33, 47) have shown that hIAPP aggregation can be proinflammatory, inducing cytokine and chemokine production in macrophages and dendritic cells in vitro.”
Self-citationNunemaker, C. S. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2846570 · Cited by 41
An update on cell intrinsic negative regulators of the NLRP3 inflammasome
Poudel, B., & Gurung, P. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0917-350r · Cited by 37
Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity
Bertinaria, M., Gastaldi, S., Marini, E., & Giorgis, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.013 · Cited by 38
“7 Metabolic and vascular diseases, such as Type 2 diabetes (T2D) and atherosclerosis, have also been linked to NLRP3 overactivation [32-36].”
BackgroundWang, W., Wu, Y., Yang, K., Wu, C., Tang, R., Li, H., & Chen, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.022 · Cited by 37
Human Amylin: From Pathology to Physiology and Pharmacology
Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 37
Lorenzo, P. I., Martín‐Montalvo, A., Cobo‐Vuilleumier, N., & Gauthier, B. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246171 · Cited by 37
“Noteworthily, the in vivo maintenance of macrophages anti-inflammatory phenotype could be achieved by blocking IL-6 signaling or by treatment with IL-4 and IL-10 [67].”
BackgroundInfluentialLin, X., Barravecchia, M., Kottmann, R. M., Sime, P. J., & Dean, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-55819-y · Cited by 36
Li, X., Xiao, G.-Y., Guo, T., Song, Y., & Li, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.986565 · Cited by 38
Galvanic current activates the NLRP3 inflammasome to promote Type I collagen production in tendon
Peñín‐Franch, A., García-Vidal, J. A., Martínez, C. M., Escolar‐Reina, P., Martínez-Ojeda, R. M., Gómez, A. I., Bueno, J. M., Minaya‐Muñoz, F., Valera‐Garrido, F., Medina‐Mirapeix, F., et al. (2022) · eLife · doi:10.7554/elife.73675 · Cited by 44
Luo, L., Zhuang, X., Fu, L., Dong, Z., Yi, S., Wang, K., Jiang, Y., Zhao, J., Yang, X., & Hei, F. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70098 · Cited by 38
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets
Weber, A. N. R., McManus, R. M., Hornung, V., Geyer, M., Kuemmerle-Deschner, J. B., & Latz, E. (2025) · Nature Immunology · doi:10.1038/s41590-025-02230-7 · Cited by 46
“…are pore-forming toxins 25,26 , ATP-activated P2X channels 25 , amyloids (for example, amyloid-β, tau, synuclein-α and islet amyloid polypeptide) 9,27,28 , as well as particles or crystals (for example, uric acid and cholesterol) 5,8 , which can cause lysosomal damage and thereby indirectly…”
Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation
Sharma, A. N., Bauer, I. E., Sanches, M., Galvez, J. F., Zunta‐Soares, G. B., Quevedo, J., Kapczinski, F. P., & Soares, J. C. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.005 · Cited by 37
“Alternatively, amyloid polypeptide from pancreatic islets in T2D patients promotes IL-1β production via protein complex NLRP3 inflammasome mediated breakdown of pro-IL-1β (Masters et al., 2010).”
BackgroundBurke, S. J., Lu, D., Sparer, T. E., Karlstad, M. D., & Collier, J. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.019 · Cited by 36
Hepatitis regulation by the inflammasome signaling pathway
Negash, A. A., & Gale, M. (2015) · Immunological Reviews · doi:10.1111/imr.12279 · Cited by 37
Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein
Shil, N. K., Pokharel, S. M., Banerjee, A. K., Hoffman, M. A., & Bose, S. (2017) · Journal of Virology · doi:10.1128/jvi.01776-17 · Cited by 36
Morikawa, S., Kaneko, N., Okumura, C., Taguchi, H., Kurata, M., Yamamoto, T., Osawa, H., Nakanishi, A., Zako, T., & Masumoto, J. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738418788749 · Cited by 37
“Consistent with the known function of NLRP3, IAPP/amylin directly interacted with LRR domain (NLRP3Exon (4-9)) of NLRP3 (Figures 4 and 5).”
BackgroundZhuang, T., Li, S., Yi, X., Guo, S., Wang, Y., Chen, J., Liu, L., Jian, Z., Gao, T., Kang, P., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00588 · Cited by 36
“It is proved that NLRP3 inflammasome mediated several inflammatory diseases including type 2 diabetes (Masters et al., 2010), inflammatory bowel disease (Cocco et al., 2017) and neurodegenerative diseases (Heneka et al., 2013).”
BackgroundTargeting the NLRP3 Inflammasome via BTK
Weber, A. N. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630479 · Cited by 37
“, 2014), type 2 diabetes (Masters et al., 2010), Alzheimer’s disease (Heneka et al.”
Complement in metabolic disease: metaflammation and a two-edged sword
King, B. C., & Blom, A. M. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00873-w · Cited by 36
Huang, K., Liang, Y., Ma, Y., Wu, J., Luo, H., & Yi, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.774272 · Cited by 43
“It has been proven that inflammation in islet of T2DM patients is due to immune cell infiltration (4), amyloid deposition (5), cell death (6), and fibrosis (7).”
Backgroundα-Arrestins and Their Functions: From Yeast to Human Health
Zbieralski, K., & Wawrzycka, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094988 · Cited by 45
“Several studies, however, presented results contradictory to the postulates mentioned above [166,167]; thus, the role of TXNIP in inflammasome activation remains pending.”
ResultRole of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes
Lee, M. (2011) · Immune Network · doi:10.4110/in.2011.11.2.95 · Cited by 35
“IAPP is able to induce NLRP3 activation and IL-1β release from dendritic cells or macrophages primed with LPS or minimally modified LDL (mmLDL), an agonist for TLR4 (22).”
BackgroundThe modern interleukin-1 superfamily: Divergent roles in obesity
Lee, M. K. S., Yvan‐Charvet, L., Masters, S. L., & Murphy, A. J. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.001 · Cited by 39
Self-citationAirway epithelial regulation of allergic sensitization in asthma
Poynter, M. E. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.04.005 · Cited by 35
“microbe-derived molecules, endogenous molecules including amyloidogenic proteins [130,131] can also activate the Nlrp3 inflammasome and induce IL-1b secretion.”
BackgroundZhang, Y., Jalili, R. B., Warnock, G. L., Ao, Z., Marzban, L., & Ghahary, A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.032 · Cited by 36
Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study
Roncero‐Ramos, I., Rangel-Zúñiga, O. A., López-Moreno, J., Alcala-Diaz, J. F., Pérez‐Martínez, P., Jiménez-Lucena, R., Castano, J. P., Roche, H. M., Delgado‐Lista, J., Ordovás, J. M., et al. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700960 · Cited by 37
Chittezhath, M., Gunaseelan, D., Zheng, X., Hasan, R., Tay, V. S. Y., Lim, S. T., Wang, X., Berggren, P., Bornstein, S. R., Boehm, B. O., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00248.2019 · Cited by 35
Javeed, N., Brown, M. R., Rakshit, K., Her, T. K., Sen, S., & Matveyenko, A. V. (2020) · Endocrinology · doi:10.1210/endocr/bqaa084 · Cited by 35
Amyloid Proteins and Peripheral Neuropathy
Albariqi, M. M. H., Engelsman, S., Eijkelkamp, N., & Höppener, J. W. M. (2020) · Cells · doi:10.3390/cells9061553 · Cited by 41
Serrano‐López, J., & Martín-Antonio, B. (2021) · Cells · doi:10.3390/cells10102562 · Cited by 40
“For instance, in type II diabetes, the aberrant activity of the NLRP3-inflammasome complex leads to IL1β secretion and caspase-1 activation that impair pancreatic β-cell function, adipocyte function and insulin sensitivity, promoting obesity and insulin resistance [42,43].”
BackgroundEmerging Roles of Myeloid-Derived Suppressor Cells in Diabetes
Wang, S., Tan, Q., Hou, Y., & Dou, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.798320 · Cited by 36
Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus
Roham, P. H., Save, S. N., & Sharma, S. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.04.001 · Cited by 37
“in macrophages can be inhibited by cytochalasin D and bafilomycin A [88].”
BackgroundIAPP boosts islet macrophage IL-1 in type 2 diabetes
Mandrup-Poulsen, T. R. (2010) · Nature Immunology · doi:10.1038/ni1010-881 · Cited by 35
“The observations by Masters et al.10 have been independently confirmed (C. Westwell-Roper & C.B. Verschere, personal communication) and provide a unifying hypothesis for the three present schools of thought about the pathogenesis of type 2 diabetes, which converge on IL-1 as a central mediator of…”
BackgroundResultThe Fine Balance of Chemokines During Disease: Trafficking, Inflammation, and Homeostasis
Cardona, S. M., Garcia, J. A., & Cardona, A. E. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-426-5_1 · Cited by 34
Mitochondria in autoinflammation: cause, mediator or bystander?
van der Burgh, R., & Boes, M. L. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.03.004 · Cited by 34
Mitchell, P. L., & Marette, A. (2014) · Diabetes · doi:10.2337/db14-1059 · Cited by 34
“Future studies also should test whether statins induce inflammasome activation and insulin resistance in other metabolic tissues such as liver and skeletal muscle, as well as in pancreatic islets where NLRP3 inflammasome activation has been linked to enhanced IL-1b and T2D pathogenesis (18,19).”
BackgroundNLRP3 Sensing of Diverse Inflammatory Stimuli Requires Distinct Structural Features
Rahman, T., Nagar, A., Duffy, E. B., Okuda, K., Silverman, N. S., & Harton, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01828 · Cited by 35
NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome
Suceveanu, A., Mazilu, L., Katsiki, N., Parepa, I. R., Voinea, F., Stoian, A. P., Rizzo, M., Botea, F., Herlea, V., Şerban, D., et al. (2020) · Metabolites · doi:10.3390/metabo10110448 · Cited by 38
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future
Murphy, A. J., & Febbraio, M. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00580-5 · Cited by 35
Guerville, F., Vialemaringe, M., Cognet, C., Duffau, P., Lazaro, E., Cazanave, C., Bonnet, F., Leleux, O., Rossignol, R., Pinson, B., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003546 · Cited by 36
Autoinflammation: translating mechanism to therapy
Doherty, T. A., Brydges, S. D., & Hoffman, H. M. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110616 · Cited by 37
Redondo‐Castro, E., Faust, D., Fox, S. G., Baldwin, A. G., Osborne, S. A., Haley, M., Karran, E. H., Nuthall, H. N., Atkinson, P. J., Dawson, L. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24029-3 · Cited by 35
The trigger for pancreatic disease: NLRP3 inflammasome
Liu, T., Wang, Q., Du, Z., Yin, L., Li, J., Meng, X., & Xue, D. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01550-7 · Cited by 33
“Some substances, such as IAPP [71] and crystalline substances [72], were identified as possible triggers of inflammasome activation in type 2 diabetes.”
BackgroundNLRP3 inflammasome pathway, the hidden balance in pregnancy: A comprehensive review
Balcı, C. N., & Acar, N. (2023) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2023.104173 · Cited by 39
Liao, Y., Kong, Y., Chen, H., Xia, J., Zhao, J., & Zhou, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113821 · Cited by 35
Alatshan, A., Kovács, G. E., Aladdin, A., Czimmerer, Z., Tar, K., & Benkő, S. (2020) · Cells · doi:10.3390/cells9071591 · Cited by 35
Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies
Lee, S. Y. H., Yates, N. J., & Tye, S. J. (2021) · The Neuroscientist · doi:10.1177/1073858421992265 · Cited by 34
Westermark, G. T., & Westermark, P. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08298.x · Cited by 33
Hull, R. L., Bogdani, M., Nagy, N., Johnson, P. Y., & Wight, T. N. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415576542 · Cited by 32
Self-citationAmylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti, J., Corrigan, R. R., Servizi, S., & Casadesús, G. (2019) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2019/1.1212 · Cited by 31
“Though several studies clearly demonstrate that human amylin and Aβ have similar effects on LTP in the CNS and use of AMYR inhibitors ameliorates these deleterious effects36-39, other evidence suggests that Aβ (1-42) is incapable of signaling through the any of the AMYR to evoke any sort of cAMP response at a wide var…”
Malik, S. S., Padmanabhan, D., & Hull-Meichle, R. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1269139 · Cited by 33
Apoptotic β-cells induce macrophage reprogramming under diabetic conditions
Ward, M., Li, G., & Hao, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004565 · Cited by 32
Söderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 32
Zhao, Q., Bi, Y., Guo, J., Liu, Y.-X., Zhong, J., Pan, L., Tan, Y. L., & Yu, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00527-x · Cited by 31
Wang, Z., Ni, X., Zhang, L., Sun, L., Zhu, X., Zhou, Q., Yang, Z., & Yuan, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s279104 · Cited by 33
Nampoothiri, M., Gurram, P. C., Manandhar, S., Satarker, S., Mudgal, J., & Arora, D. S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220413090541 · Cited by 33
Linking hIAPP misfolding and aggregation with type 2 diabetes mellitus: a structural perspective
Hassan, S., White, K., & Terry, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211297 · Cited by 36
Xu, H., Li, W., Hong, S., Shao, J., Chen, J.-H., Chattipakorn, N., Wu, D., Luo, W., & Liang, G. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01040-z · Cited by 32
“Aberrant activation of NLRP3 inflammasome leads to atherosclerosis [29], type 2 diabetes [26], ulcerative colitis [28], and gouty arthritis [27].”
BackgroundInflammasome activation and metabolic disease progression
Li, H., Jin, C., Chen, Y., & Flavell, R. A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.020 · Cited by 32
“NLRP3 inflammasome activation in cultured macrophages and DCs [87].”
BackgroundMitochondria–Endoplasmic Reticulum Contact Sites Mediate Innate Immune Responses
Misawa, T., Takahama, M., & Saitoh, T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-4567-7_14 · Cited by 32
Hyperamylinemia Increases IL-1β Synthesis in the Heart via Peroxidative Sarcolemmal Injury
Liu, M., Verma, N., Peng, X., Srodulski, S. J., Morris, A. J., Chow, M., Hersh, L. B., Chen, J., Zhu, H., Netea, M. G., et al. (2016) · Diabetes · doi:10.2337/db16-0044 · Cited by 31
Metadata
- Authors
- Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., Mullooly, N., Mielke, L. A., Harris, J., Coll, R. C., Mills, K. H. G., Mok, K. H., Newsholme, P., Nuñez, G., Yodoi, J., Kahn, S. E., Lavelle, E. C., & O'Neill, L. A. J.
- Affiliations
- Trinity College Dublin (IE)
- University of Washington (US)
- University of Michigan (US)
- Kyoto University (JP)
- University College Dublin (IE)
- Corresponding author
- Masters, Seth L
- ORCID
- Venue
- Nature Immunology
- Published
- 2010-09-12
- Volume
- 11
- Issue
- 10
- Pages
- 897-904
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC3103663
- OpenAlex
- W2034946303
- Cited by
- 1,330
- References
- 55
- Citations by year
- 2026: 58 · 2025: 57 · 2024: 64 · 2023: 75 · 2022: 71 · 2021: 99 · 2020: 100 · 2019: 95 · 2018: 82 · 2017: 83 · 2016: 73 · 2015: 101 · 2014: 95 · 2013: 112 · 2012: 83
- FWCI
- 35.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- eSpace (Curtin University) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI063331, R56AI063331, R01AI063331, R37AI063331)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-75998, R01DK075998)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- NLRP3 inflammasome, amylin, IL-1β, type 2 diabetes, beta cell destruction, glibenclamide, LDL oxidation, glucose metabolism, inflammasome priming, pancreatic islets, macrophages, amyloid deposition
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Amyloid, Animals, Carrier Proteins, Cells, Cultured, Dendritic Cells, Diabetes Mellitus, Type 2, Glyburide, Humans, Hypoglycemic Agents, Islets of Langerhans, Macrophages, Mice, Inbred C57BL, Mice, Transgenic, Receptors, Cytoplasmic and Nuclear, Mice, Rats, Interleukin-1beta, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
